Exelixis, Inc. (EXEL) is a leading biopharmaceutical company that is ideally positioned to focus on the discovery, development, and commercialization of new and innovative medicines that can drastically enhance the lives of patients battling cancer. The company is headquartered in Alameda, California, and has been in operation since 1994.
Exelixis is best known for its targeted therapy drug, Cabometyx (cabozantinib), which is approved for the treatment of several types of cancers, including advanced renal cell carcinoma (RCC, a type of kidney cancer) and hepatocellular carcinoma (HCC, a type of liver cancer). The drug works by blocking the growth of new blood vessels that feed a tumor. Apart from Cabometyx, Exelixis has also developed other drugs such as Cometriq and Cotellic, and is continuously working on new drug candidates to further expand its product portfolio.
The company operates on a business model that combines internal product development with strategic corporate alliances and business development activities. This strategy has allowed Exelixis to access resources, share risk and attract significant capital over the course of its existence, thereby building a robust product pipeline and achieving financial stability.
Exelixis, Inc. is deeply committed to the principle of doing "good science that matters." The company employs a team of skilled, passionate professionals who are relentless in their pursuit of new scientific understandings and clinical breakthroughs. Exelixis highly values collaboration, teamwork, and integrity, ensuring a conducive working environment for innovation to flourish.
Corporate social responsibility is also a key component of Exelixis' mission. The company is committed to improving access to its therapies, supporting patient groups and contributing to the broader community. It is also focused on reducing its environmental impact and promoting sustainable practices.
On the financial front, Exelixis continues to deliver strong performance with a steady stream of revenue from its approved products and clinical developments. It has a solid balance sheet with sufficient liquidity to meet its expansion requirements and uphold research and development activities.
In the ever-evolving biopharmaceutical industry, Exelixis offers a compelling mix of current successful cancer treatments and promising pipeline products, a sound business strategy, robust financial health and a strong commitment to patients. This positions them firmly for continued growth and further achievements in their mission to help cancer patients recover stronger and live longer.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Exelixis (EXEL) announced that the FDA has extended its review period for zanzalintinib plus atezolizumab for metastatic colorectal cancer after the company submitted new safety and efficacy data. This extension, while causing a delay, is seen as an opportunity for Exelixis to strengthen the regimen's position as a durable treatment option. The company aims to diversify its oncology portfolio beyond cabozantinib, with zanzalintinib being a key component in its future growth strategy.
Exelixis (EXEL) announced a three-month extension for the FDA's review of zanzalintinib, pushing the target action date to March 3, 2027. The extension followed a major amendment submission with updated safety and efficacy data. The article discusses the bull and bear cases for approval, highlighting the positive overall-survival in the full STELLAR-303 study population versus the lack of statistical significance in a specific subgroup and treatment burden.
Exelixis (EXEL) has announced a three-month extension of the FDA's review for its drug zanzalintinib, setting a new target action date of March 3, 2027. This extension, due to an FDA request for updated safety and efficacy information classified as a major amendment, leaves the drug's approval unresolved. The article discusses the bull and bear cases for zanzalintinib's approval, highlighting a positive overall survival benefit in the full study population against concerns about a subgroup analysis and increased treatment burden.
Exelixis (NASDAQ: EXEL) saw its stock slip after the FDA extended the review period for its cancer drug zanzalintinib by three months. The delay, attributed to Exelixis submitting updated safety and efficacy data, pushed the Prescription Drug User Fee Act action date to March 3, 2027. Despite the short-term market volatility, analyst Andy Hsieh from William Blair believes the risk of rejection remains low and the long-term revenue potential for zanzalintinib should not be significantly diminished.
Exelixis (NASDAQ:EXEL) shares dropped 3.5% after the FDA extended the review period for its new drug application for zanzalintinib by three months. The extension, triggered by the company's submission of updated safety and efficacy data, pushes the Prescription Drug User Fee Act action date to March 3, 2027. Zanzalintinib is being evaluated in combination with atezolizumab for metastatic colorectal cancer.
Exelixis (EXEL) has seen its shares rise 13.3% since its last earnings report, outperforming the S&P 500. The company reported strong Q2 adjusted EPS, beating estimates, though revenue missed expectations. Despite lowering its 2026 revenue outlook due to a slower-than-projected ramp-up in a neuroendocrine tumor indication, Exelixis continues to advance its zanzalintinib pipeline and share repurchase program.
Exelixis has won an appeal in a patent case against MSN Laboratories. The article, published on August 31, 2026, reports on this legal victory without providing further details on the case itself. It also briefly mentions other recent news for Exelixis, including its Q2 2026 earnings call and revenue guidance.
Exelixis (EXEL) is increasing shareholder value through significant share buybacks, funded by the strong performance of its oncology drug, CABOMETYX. Despite a recent cut in revenue guidance, the company's free cash flow remains stable, supporting its buyback program. The future growth largely depends on the regulatory approval of its next potential franchise drug, zanzalintinib, which awaits a decision in December 2026.
BlackRock Inc. has acquired a new 29.1 million-share stake in Exelixis (NASDAQ:EXEL), valued at approximately $1.58 billion, representing 11.57% of the biotechnology company. Institutional investors now own 85.27% of EXEL, which recently reported strong quarterly earnings of $0.91 EPS, beating estimates, though revenue was slightly below expectations. Despite insiders selling shares, analysts generally maintain a "Hold" rating with an average price target of $50.07 for Exelixis.